CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present CAT-2054, a potential treatment for NASH and hypercholesterolemia, at the upcoming National Lipid Association 2016 Scientific Sessions held May 19 - 22, 2016, in New Orleans at the New Orleans Hyatt Regency Hotel.
